跳至主要内容
临床试验/ISRCTN13479086
ISRCTN13479086进行中(未招募)未知

Sex differences in the role of sympathetic nerve activity in the development of hypertension in humans

niversity of Bristol0 个研究点目标入组 148 人开始时间: 2019年6月28日最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
发起方
入组人数
148

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

性别
All

入选标准

  • 1. Aged 18-75 years
  • 2. Hypertensive patients: Office blood pressure = 140/90 mmHg and daytime ambulatory blood pressure =135/85 mmHg
  • 3. Normotensive participants: Office blood pressure < 140/90 mmHg and daytime ambulatory blood pressure < 135/85 mmHg
  • 4. Postmenopausal women: No period for at least 12 months and not using hormonal contraception (NICE, 2015)

排除标准

  • 1. Secondary causes of hypertension
  • 2. Body mass index > = 30 kg/m2
  • 3. Oophorectomy (removal of ovaries) prior to onset of natural menopause
  • 4. Pregnancy/breastfeeding women
  • 5. Taking hormone replacement therapy
  • 6. Taking nitrate, steroid, anti-coagulant or immunosuppressant medication or medication as part of a clinical trial
  • 7. Major illness e.g. cancer, inflammatory disease (including vasculitis) or receiving palliative care
  • 8. Diagnosed cardiovascular (including arrhythmia), respiratory (including asthma), psychiatric, renal or ophthalmic disease
  • 9. Congenital or acquired neurological conditions (including dementia), language disorders, repeated or chronic pain conditions (excluding menstrual pain and minor sporadic headaches)
  • 10. Diabetes
  • 11. Symptoms of febrile illness less than a week before experiment
  • 12. Excessive alcohol consumption (> 28 units/week) or use of illicit drugs
  • 13. Needle phobia
  • 14. Inability to understand instructions given in English
  • 15. Mild, moderate or severe persistent asthma (due to potential broncho effects of a systemic beta-blocker)
  • For premenopausal women and younger men only (relating to the propranolol infusion):
  • 1. Individuals with any of the conditions listed in the instructions for use document of Dociton solution of injection (propranolol hydrochloride) in which Dociton must not be used:
  • 1.1. Hypersensitivity to propranolol/beta-blockers or other ingredients in Dociton
  • 1.2. Heart muscle weakness
  • 1.3. Shock
  • 1.4. Grade II or III AV block
  • 1.5. Sick sinus syndrome
  • 1.6. Sino-atrial block
  • 1.7. Bradycardia (resting pulse < 50 beats/min)
  • 1.8. Hypotension
  • 1.9. Acidosis
  • 1.10. Taking MAO inhibitors
  • 1.11. Late stage peripheral blood flow disorders
  • 1.12. tendency towards bronchial spasm e.g. bronchial asthma.
  • 2. Individuals with any condition listed in the instructions for use document in which Dociton should be used with caution:
  • 2.1. Grade I AV block
  • 2.2. Diabetes mellitus
  • 2.3. Lengthy strict fasting and severe physical stress
  • 2.4. Phaeochomocytoma
  • 2.5. Impaired liver or kidney function
  • 2.6. Individual/family history of psoriasis
  • 2.7. History of severe hypersensitivity reaction or receiving treatment to weaken allergic reactivity).
  • 3. Individuals taking/recently taken any medication listed in the instructions for use document as being affected by Dociton or affecting Dociton:
  • 3.1. Insulin/oral antidiabetics
  • 3.2. Other blood pressure-lowering medications, nitroglycerin, diuretics, vasodilators, tricyclic antidepressants, phenothiazines, barbituates
  • 3.3. Calcium antagonists of the nifedipine type
  • 3.4. Calcium antagonists of the verapamil or diltiazem type
  • 3.5. Antiarrhythmics, e.g. disopyramine or others
  • 3.6. Cardiac glycosides
  • 3.7. Reserpine
  • 3.8. Alpha-methyldopa

研究者

发起方
niversity of Bristol

相似试验